Demant (CPSE:DEMANT), What Is Behind The Fresh Attention?

Demant (CPSE:DEMANT) has drawn fresh investor attention after releasing H1 2026 results showing higher sales and earnings, upgrading its full year outlook, and spotlighting AI powered products such as Oticon Zeal and the newly launched Oticon Reveal.

See our latest analysis for Demant.

The recent H1 2026 earnings upgrade and the launch of AI powered Oticon Reveal appear to have supported strong momentum in Demant’s share price. The 90 day share price return is 23.83% and the year to date share price return is 36.83%, even though the 5 year total shareholder return is down 16.57%.

If Demant’s AI push has caught your interest, it could be a good moment to see what other healthcare focused AI stocks are doing through the 133 healthcare AI stocks

After a sharp rerating and a share price slightly above the average analyst target, the bigger gap for Demant now sits between that market price and some higher intrinsic value estimates. Where does a reasonable fair value line up in that spread?

Most Popular Narrative: 5.5% Overvalued

Demant’s last close at DKK292 sits modestly above the most followed fair value estimate of DKK276.90, which is built using a 6.2% discount rate and detailed long term earnings forecasts.

Continued heavy investment in R&D and ongoing commitment to launching two major product updates annually (with a robust pipeline), including advancements in AI-enabled and connected hearing devices, position Demant to capture premium share with differentiated features, positively impacting future net margins and maintaining pricing power as digital adoption accelerates.

Read the complete narrative.

Curious what kind of revenue uplift, margin rebuild, and future earnings multiple need to line up for that DKK276.90 figure? The full narrative spells out the exact growth, profitability and valuation path that has to fall into place for Demant to meet those expectations.

Result: Fair Value of DKK276.90 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there is still clear downside risk for Demant if consumer caution keeps hearing aid upgrades subdued, or if competition forces weaker pricing and margins than analysts expect.

Find out about the key risks to this Demant narrative.

Another View on Demant’s Valuation

While the most popular narrative pegs Demant at about 5.5% above its DKK276.90 fair value, the SWS DCF model paints a very different picture. On that view, Demant at DKK292 trades at a large discount to an intrinsic value estimate of DKK528.09, which raises a clear question: Is the market overpaying for near term caution or underpricing the company’s longer term cash flows?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Given the split opinion around Demant’s fair value, it makes sense to review the numbers yourself and decide how the risks and rewards line up for your own portfolio. You can get a balanced view of both sides by checking the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Demant?

If Demant has sharpened your focus on opportunities, do not stop here. Use the same structured approach to spot other stocks that fit your goals.

• Spot potential bargains early and scan for companies that look mispriced relative to their quality through the 252 high quality undervalued stocks.
• Build more dependable income by checking out stocks that appear in the 445 dividend fortresses and may support stronger yield focused portfolios.
• Strengthen your downside protection by reviewing companies that show up in the 298 resilient stocks with low risk scores before the next wave of headlines hits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com